TITLE:
Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents

CONDITION:
Bipolar Disorder

INTERVENTION:
Lithium carbonate

SUMMARY:

      This study will evaluate the effectiveness of the medications, lithium (Eskalith),
      valproate (Depakote), and risperidone (Risperdal) in treating children and adolescents
      with bipolar disorder or symptoms of mania.
    

DETAILED DESCRIPTION:

      Patients are randomly assigned to receive lithium (Eskalith), valproate (Depakote), or
      risperidone (Risperdal) for 8 to 16 weeks. They will have weekly visits to monitor their
      response to the medication. When the study is complete, care will be transferred to the
      child's treating psychiatrist.
    

ELIGIBILITY:
Gender: All
Age: 6 Years to 15 Years
Criteria:

        Inclusion Criteria:

          -  DSM-IV criteria for bipolar I (manic or mixed) or mania for at least 4 weeks

          -  CGAS less than or equal to 60

          -  Good physical health

        Exclusion Criteria:

          -  Schizophrenia or any pervasive developmental disorder

          -  Major medical or neurological disease

          -  History of addiction to illicit substances or alcohol or drug abuse within the last 4
             weeks

          -  IQ less than 70

          -  Pregnancy or breast-feeding

          -  Unacceptable methods of contraception

          -  In-patient care at baseline
      
